Chief Executive Officer of Txcell, Stéphane Boissel has a strong experience in both investment banking and the immunotherapy space. In the early part of his career, from 1990 to 2002, Stéphane worked at PWC and then for the investment banking group Lazard, where he mostly worked in principal investment in France, Singapore and Hong Kong.
Thereafter, he worked at Innate Pharma from 2002 to 2010, firstly as CFO and then as EVP and CFO. From 2010 to 2014, he was Deputy-CEO of Transgene. During his tenure at both Transgene and Innate Pharma, he led several rounds of private and public placement and negotiated several international business deals. Stéphane was also a member of the Board of Directors of Erytech Pharma from 2005 to 2010 and CEO of Genclis, a molecular diagnostic company (2014).
Stéphane Boissel studied management and finance at the University of Lyon, France, graduated at Paris-Dauphine and obtained his MBA from the University of Chicago (Booth GSB), USA.